SymBio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
SymBio Pharmaceuticals has been growing earnings at an average annual rate of 21.7%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 14% per year.
Key information
21.7%
Earnings growth rate
35.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 14.0% |
| Return on equity | -77.9% |
| Net Margin | -131.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Hopeful That SymBio Pharmaceuticals (TSE:4582) Will Use Its Cash Wisely
Sep 24
SymBio Pharmaceuticals Limited's (TSE:4582) 31% Share Price Surge Not Quite Adding Up
Aug 06Why Investors Shouldn't Be Surprised By SymBio Pharmaceuticals Limited's (TSE:4582) 28% Share Price Surge
Jun 11Here's Why We're Watching SymBio Pharmaceuticals' (TYO:4582) Cash Burn Situation
Feb 09If You Had Bought SymBio Pharmaceuticals' (TYO:4582) Shares Five Years Ago You Would Be Down 58%
Dec 18Revenue & Expenses Breakdown
How SymBio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,067 | -4,019 | 568 | 5,131 |
| 30 Jun 24 | 3,695 | -3,424 | 2,777 | 2,638 |
| 31 Mar 24 | 4,642 | -2,743 | 2,669 | 2,638 |
| 31 Dec 23 | 5,589 | -1,962 | 2,584 | 2,638 |
| 30 Sep 23 | 7,074 | -1,164 | 2,964 | 2,554 |
| 30 Jun 23 | 8,313 | -8 | 2,967 | 2,554 |
| 31 Mar 23 | 9,237 | 1,020 | 2,886 | 2,554 |
| 31 Dec 22 | 10,008 | 1,179 | 3,082 | 2,554 |
| 30 Sep 22 | 10,059 | 3,262 | 4,590 | 450 |
| 30 Jun 22 | 9,983 | 3,346 | 4,128 | 824 |
| 31 Mar 22 | 9,152 | 2,405 | 3,689 | 1,263 |
| 31 Dec 21 | 8,257 | 2,032 | 3,048 | 1,736 |
| 30 Sep 21 | 6,208 | -1,071 | 1,649 | 3,553 |
| 30 Jun 21 | 4,773 | -2,411 | 2,454 | 3,179 |
| 31 Mar 21 | 3,856 | -3,308 | 2,724 | 2,740 |
| 31 Dec 20 | 2,987 | -4,090 | 3,066 | 2,267 |
| 30 Sep 20 | 3,162 | -3,430 | 4,331 | 470 |
| 30 Jun 20 | 2,193 | -4,191 | 1,497 | 3,275 |
| 31 Mar 20 | 1,778 | -4,751 | 2,152 | 2,880 |
| 31 Dec 19 | 2,838 | -4,376 | 2,705 | 2,442 |
| 30 Sep 19 | 2,811 | -4,452 | 1,273 | 3,805 |
| 30 Jun 19 | 3,912 | -3,434 | 1,661 | 2,795 |
| 31 Mar 19 | 4,559 | -2,610 | 1,747 | 2,304 |
| 31 Dec 18 | 3,836 | -2,753 | 1,977 | 1,833 |
| 30 Sep 18 | 4,060 | -2,373 | -695 | 4,311 |
| 30 Jun 18 | 3,587 | -4,100 | 1,263 | 3,856 |
| 31 Mar 18 | 3,463 | -4,155 | 1,733 | 3,434 |
| 31 Dec 17 | 3,444 | -3,978 | 1,949 | 3,018 |
| 30 Sep 17 | 3,377 | -3,943 | 814 | 4,378 |
| 30 Jun 17 | 2,943 | -2,404 | 1,035 | 2,507 |
| 31 Mar 17 | 3,045 | -2,243 | 1,147 | 2,062 |
| 31 Dec 16 | 2,368 | -2,313 | 1,353 | 1,667 |
| 30 Sep 16 | 2,008 | -3,488 | 735 | 3,016 |
| 30 Jun 16 | 2,168 | -3,131 | 864 | 2,553 |
| 31 Mar 16 | 1,718 | -2,864 | 987 | 2,258 |
| 31 Dec 15 | 1,933 | -2,632 | 1,088 | 2,035 |
| 30 Sep 15 | 1,939 | -1,232 | 512 | 1,372 |
| 30 Jun 15 | 1,956 | -1,077 | 681 | 1,178 |
| 31 Mar 15 | 2,190 | -1,082 | 846 | 980 |
| 31 Dec 14 | 1,955 | -1,116 | 1,047 | 774 |
| 30 Sep 14 | 1,557 | -1,358 | 248 | 1,598 |
| 30 Jun 14 | 1,697 | -1,506 | 471 | 1,423 |
| 31 Mar 14 | 1,217 | -1,707 | 716 | 1,232 |
| 31 Dec 13 | 1,532 | -1,605 | 939 | 1,053 |
Quality Earnings: 4582 is currently unprofitable.
Growing Profit Margin: 4582 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4582 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.7% per year.
Accelerating Growth: Unable to compare 4582's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4582 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: 4582 has a negative Return on Equity (-77.93%), as it is currently unprofitable.